Intellectual Property
Viewpoints
Filter by:
Practical Guidelines for Avoiding Patent Term Adjustment Penalty
March 1, 2024 | Blog | By Alex Trimble, PhD
Another Implementer Hold Out Door Closes: The Death of the Anti-Suit Injunction?
February 28, 2024 | Blog | By Daniel Weinger, Andrew DeVoogd, Courtney Herndon, Laura Petrasky
Need Prior Art? Here’s How to Search the PTO Database of Patents Like a Patent Examiner
February 12, 2024 | Blog | By Andrew DeVoogd, Adam Banes
The United States Patent and Trademark Office (USPTO) released the web-based Patent Public Search tool ("PPS") in late 2021. This useful tool is comparable to the search tool that the PTO’s own examiner’s use to find prior art. That said, PPS has a real learning curve in developing effective search queries. In this article we offer a starting point in developing search queries that will return relevant results.
Read more
How Your Trade Secret Could Help to Defend Against Claims of Patent Infringement
February 1, 2024 | Blog | By Adam Samansky, Peter Cuomo, Nicholas Armington , Stephen Chen
How Compulsory Licenses Can Affect Domestic and Foreign Prosecution
January 24, 2024 | Blog | By Michael Van Loy, Sophia Petrichenko
Year in Review: The Most Popular IP Posts of 2023
January 4, 2024 | Blog | By Christina Sperry
Supercapacitor Patent Row Between CAP-XX and Maxwell Technologies Goes to Court this Week
December 13, 2023 | Blog | By Brad M Scheller , Amy LoBue
Basics – How an Inventor’s Own Work Affects Patent Applications
December 6, 2023 | Blog | By Peter Hecker, PhD, Lee Johnson, PhD
The Impact of Venture Capital Funding on Entity Status
November 10, 2023 | Blog | By Michael Van Loy, Jessica Zhang, Qi Zhang
Understanding the implications of venture capital funding on a company’s size classification is crucial, especially when it jeopardizes its “small entity” status and raises concerns with the United States Patent and Trademark Office. Member Michael D. Van Loy, PhD and Associates Jessica Zhang and Qi Zhang break down these complexities, underscoring the importance of accurately determining entity status to avoid pitfalls such as patent invalidation.
Read more
AI-Based Patent Applications: Recent History and the Future
October 30, 2023 | Blog | By Vishak Ganesh, Frank Gerratana
Distinguishing Patent Protection from Patient Safety – A Role for the FDA
August 21, 2023 | Blog | By Peter Hecker, PhD, Lee Johnson, PhD
An Overview of Shotgun Pleadings in the Federal Courts
August 7, 2023 | Blog | By Joe Rutkowski, Peter Cuomo
Why Pharma Companies Should File Patents Later In The R&D Process
July 25, 2023 | Blog | By Alex Trimble, PhD
Clinical trial related patent applications are often filed prior to the start of the Phase I clinical trial to minimize the risk of invalidation of the resulting patent for public use (35 U.S.C. § 102(a)) based on the clinical trial itself. This conservative filing strategy is unnecessary for the majority of clinical trial-related inventions, and reduces the value of the patent by prematurely starting the patent term clock.
Read more
Viewpoint Editors
Brad M. Scheller
Member
Christina Sperry
Member
Explore Other Viewpoints:
- Antitrust
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Cross-Border Asset Recovery
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- Energy & Sustainability
- Environmental Enforcement Defense
- Environmental Law
- FDA Regulatory
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Transactions
- Real Estate, Construction & Infrastructure
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- Strategic IP Monetization & Licensing
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology